Viking Therapeutics is a biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. The company's main clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta in development for patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's second clinical program's primary drug candidate, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in development for patients recovering from non-elective hip fracture surgery. The company is also developing VK0214 for X-linked adrenoleukodystrophy.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.